Literature DB >> 11317228

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.

V S Basile1, V Ozdemir, M Masellis, H Y Meltzer, J A Lieberman, S G Potkin, F M Macciardi, A Petronis, J L Kennedy.   

Abstract

Tardive dyskinesia (TD) is a disabling neurological side effect associated with long-term treatment with typical antipsychotics. Family studies and animal models lend evidence for hereditary predisposition to TD. The newer atypical antipsychotics pose a minimal risk for TD which is in part attributed to their ability to block the serotonin-2A (5-HT(2A)) receptor. 5-HT(2A) receptors were also identified in the basal ganglia; a brain region that plays a critical role in antipsychotic-induced movement disorders. We tested the significance of variation in the 5-HT(2A) receptor gene (HTR2A) in relation to the TD phenotype. Three polymorphisms in HTR2A, one silent (C102T), one that alters the amino acid sequence (his452tyr) and one in the promoter region (A-1437G) were investigated in 136 patients refractory or intolerant to treatment with typical antipsychotics and with a DSM-IIIR diagnosis of schizophrenia. We did not find any significant difference in allele, genotype or haplotype frequencies of polymorphisms in HTR2A among patients with or without TD (P > 0.05). Further analysis using the ANCOVA statistic with a continuous measure of the TD phenotype (Abnormal Involuntary Movement Scale (AIMS) score) found that the AIMS scores were not significantly influenced by HTR2A polymorphisms, despite controlling for potential confounders such as age, gender and ethnicity (P > 0.05). Theoretically, central serotonergic function can be subject to genetic control at various other mechanistic levels including the rate of serotonin synthesis (tryptophane hydroxylase gene), release, reuptake (serotonin transporter gene) and degradation (monoamine oxidase gene). Analyses of these other serotonergic genes are indicated. In summary, polymorphisms in HTR2A do not appear to influence the risk for TD. Further studies evaluating in tandem multiple candidate genes relevant for the serotonergic system are warranted to dissect the genetic basis of the complex TD phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11317228     DOI: 10.1038/sj.mp.4000847

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  16 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

2.  Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms.

Authors:  Cüneyt Güzey; Maria Gabriella Scordo; Edoardo Spina; Veslemøy Malm Landsem; Olav Spigset
Journal:  Eur J Clin Pharmacol       Date:  2007-01-17       Impact factor: 2.953

Review 3.  Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics.

Authors:  Wolfgang Maier; Astrid Zobel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 4.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

5.  Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients.

Authors:  Chiara Fabbri; Daniel Souery; Raffaella Calati; Concetta Crisafulli; Armando Chierchia; Diego Albani; Gianluigi Forloni; Alberto Chiesa; Rosalba Martines; Othman Sentissi; Julien Mendlewicz; Giovanni De Girolamo; Alessandro Serretti
Journal:  J Neural Transm (Vienna)       Date:  2014-08-17       Impact factor: 3.575

Review 6.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 7.  Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation.

Authors:  Bernard Lerer; Ronnen H Segman
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 8.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 9.  Genetics of antipsychotic-induced side effects and agranulocytosis.

Authors:  Nabilah I Chowdhury; Gary Remington; James L Kennedy
Journal:  Curr Psychiatry Rep       Date:  2011-04       Impact factor: 5.285

10.  Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice.

Authors:  J J Crowley; D E Adkins; A L Pratt; C R Quackenbush; E J van den Oord; S S Moy; K C Wilhelmsen; T B Cooper; M A Bogue; H L McLeod; P F Sullivan
Journal:  Pharmacogenomics J       Date:  2010-11-16       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.